From the miRoncol archive: This historical update may contain promotional language or research findings that do not describe the current service. Retrospective research results do not establish prospective screening performance, and references to scientific prizes do not imply evaluation or endorsement of miRoncol or miCheckup. Do not rely on this archive for healthcare decisions; use the current product information and discuss screening decisions with a healthcare professional.
miRoncol presented a poster at the 2022 American Association for Cancer Research Annual Meeting describing development and retrospective evaluation of a four-microRNA model using serum samples from cancer and non-cancer datasets.
The results were research findings from the described datasets. They do not establish prospective screening performance, clinical utility or suitability for an individual, and performance varied by cancer type. Read the conference abstract.